Lu-177

Lu-177 NCA

non carrier added
Lu-177 NCA Isotope

Specifications

AVAILABILITY
HALF-LIFE
6.65 days

Available as:

⦁ Radiochemical
⦁ cGMP Radiopharmaceutical
APPLICATION: 177Lu has virtually pervaded all areas of in vivo radionuclide therapy and may be poised to become a key therapeutic radionuclide of choice for targeted radionuclide therapy (TRT).
CHARACTERISTICS: Lutetium-177 is a beta emitter (β-) at 498keV (78.6%) and 177 keV (12.2%) decaying into stable Hafnium-177.
PROCESS DATA
GROWING ATTENTION
Medical solutions for nuclear medicine
Production of 177Lu for Targeted Radionuclide Therapy: Available Options
Medical solutions for treatment of cancer - RADIOPHARMACEUTICAL
Estimation of whole body radiation exposure to nuclear medicine personnel during synthesis of 177lutetium-labeled radiopharmaceuticals
	Studies on 177Lu-labeled methylene diphosphonate as potential bone-seeking radiopharmaceutical for bone pain palliation.
Studies on 177Lu-labeled methylene diphosphonate as potential bone-seeking radiopharmaceutical for bone pain palliation.